DPC4 gene mutation in colitis associated neoplasia

A T M S Hoque, S A Hahn, M Schutte, S E Kern

Abstract

Background—Colitis associated dysplasia and cancer often have deletions involving the long arm of chromosome 18q, suggesting the location of a tumour suppressor gene critical for their tumorigenesis. The DPC4 gene, which is genetically inactivated in pancreatic and other cancers, has recently been described.

Aim—Because DPC4 is located at 18q21-1, the hypothesis that it could be a mutated tumour suppressor gene in colitis associated neoplasms was tested.

Patients—Advanced neoplastic lesions from six patients having chronic colitis were analysed for DPC4.

Methods—Individual exons of DPC4 were amplified by the polymerase chain reaction (PCR) and sequenced from genomic DNA of tissue specimens dissected by cryostat.

Results—DPC4 was found to have biallelic inactivation in one of three neoplasms shown to have allelic loss of 18q. The mutation had been acquired somatically in a plaque of high grade dysplasia. The mutation created a non-sense codon, which would cause premature termination of protein translation.

Conclusion—The DPC4 gene is a target of 18q LOH events in colitis associated neoplasia.

(Gut 1997; 40: 120-122)

Keywords: LOH, loss of heterozygosity, in vitro synthesised protein assay, in vitro synthesis.

Chronic ulcerative colitis and Crohn’s disease are associated with an increased risk of colorectal neoplasia. Detailed studies to show the genetic alterations in these neoplasms identified K-ras mutations, 17p deletions, and p53 mutations, 5q deletions, APC mutations, and 18q deletions at significant rates.1-8 Thus the types of genetic alterations in these neoplasms were not distinctly different from those seen in sporadic colorectal adenomas and carcinomas. Allelic losses of 18q are among the most common deletions seen in a large variety of human malignancies.9-10 One candidate tumour suppressor gene on chromosome 18q is the DCC gene. However, DCC is among the largest genes known, and mutational analyses have been difficult.11 We recently identified another candidate tumour suppressor gene at 18q21-1, DPC4 (deleted in pancreatic carcinoma, locus 4).10 DPC4 was genetically inactivated by homozygous deletion in a third of pancreatic carcinomas. On sequencing the coding region of DPC4, performed in tumours without homozygous deletion, intragenic mutations were identified in another 20% of the carcinomas. The finding of homozygous deletions of DPC4 in single cases of bladder and biliary cancer, as well as in two colorectal cancers,10 suggested that DPC4 might also be involved in other types of tumour. Here we analysed the mutational status of DPC4 in colitis associated colorectal neoplasms.

Methods

Patients and Specimens

Specimens were obtained from six patients with colitis associated neoplasia that were resected at The Johns Hopkins Hospital between the years 1989 and 1993. This is a well characterised set of patients, and extensive molecular genetic profiles have been published.1 2 Clinical information about the patients was obtained from chart review (Table I). Lesions were classified according to the 1983 Inflammatory Bowel Disease—Dysplasia Morphology Study Group Criteria (IBD-DMSGC), and diagnoses were confirmed by at least four experienced gastrointestinal pathologists.3 4 Patients CC-1, CC-2, CC-4, and CC-6 had ulcerative colitis and patients CC-3 and CC-5 had Crohn’s disease. All patients had pancolitis except CC-1. Patient CC-4 had high grade dysplasia and all others had carcinoma. For each patient, the most advanced lesion was examined for mutations. For CC-6, two histologically distinct areas of a carcinoma were analysed.

Table 1

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age at operation (y)</th>
<th>Type</th>
<th>Extent</th>
<th>Duration of colitis (y)</th>
<th>Site</th>
<th>Lesion</th>
</tr>
</thead>
<tbody>
<tr>
<td>CC-1</td>
<td>71</td>
<td>UC</td>
<td>Unknown</td>
<td>16</td>
<td>Rectum</td>
<td>Dukes' C non-mucinous carcinoma</td>
</tr>
<tr>
<td>CC-2a</td>
<td>45</td>
<td>UC</td>
<td>Pancolitis</td>
<td>&gt; 10</td>
<td>Ascending</td>
<td>Dukes' C non-mucinous carcinoma</td>
</tr>
<tr>
<td>CC-3</td>
<td>40</td>
<td>CD</td>
<td>Pancolitis</td>
<td>25</td>
<td>Rectum</td>
<td>Dukes' B mucinous carcinoma</td>
</tr>
<tr>
<td>CC-4</td>
<td>43</td>
<td>UC</td>
<td>Pancolitis</td>
<td>&gt; 20</td>
<td>Ascending</td>
<td>Plaque of high grade dysplasia. No carcinoma</td>
</tr>
<tr>
<td>CC-5a</td>
<td>58</td>
<td>CD</td>
<td>Pancolitis</td>
<td>37</td>
<td>Rectum</td>
<td>Dukes' A mucinous carcinoma</td>
</tr>
<tr>
<td>CC-6a</td>
<td>35</td>
<td>UC</td>
<td>Pancolitis</td>
<td>12</td>
<td>Ascending</td>
<td>Dukes' C carcinoma, non-mucinous area</td>
</tr>
<tr>
<td>CC-6b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dukes' C carcinoma, mucinous area</td>
</tr>
</tbody>
</table>

*From a well characterised patient group described in part in previous publications.1 2 UC=Ulcerative colitis; CD=Crohn’s disease.
TABLE II  
**DPC4 primers used in the polymerase chain reaction and cycle sequencing**

<table>
<thead>
<tr>
<th>Exon</th>
<th>PCR primers*</th>
<th>Sequencing primer†</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>AAGTATGCACTGACGGCAAGTTTAG</td>
<td>TACCTTCTGCTGGCCATG</td>
</tr>
<tr>
<td>2</td>
<td>GTATGACATGGCCAAGTTTAG</td>
<td>GTATGACATGGCCAAGTTTAG</td>
</tr>
<tr>
<td>3</td>
<td>TATGACATGGCCAAGTTTAG</td>
<td>GTATGACATGGCCAAGTTTAG</td>
</tr>
<tr>
<td>4</td>
<td>TGTATGACATGGCCAAGTTTAG</td>
<td>GTATGACATGGCCAAGTTTAG</td>
</tr>
<tr>
<td>5/6</td>
<td>CAGTTTCTGTCTGCTAGGAG</td>
<td>CAGTTTCTGTCTGCTAGGAG</td>
</tr>
</tbody>
</table>

*For PCR, exons 5 and 6 are coamplified using a single primer pair.
†For sequencing, exon 5 requires a single sequencing primer, and is listed first. Exon 6 requires two primers due to its larger size.

**DPC4 MUTATION DETECTION**
Amplification by polymerase chain reaction (PCR) and cycle sequencing of exons 1 through 11 was performed. Primers (Table II) were derived from intronic or non-coding regions and used for PCR amplification of the 11 exons from genomic DNA of each lesion. Products from PCR were treated with exonuclease I and shrimp alkaline phosphatase, according to the manufacturer’s recommendations (USB, Cleveland, OH, USA). Direct sequencing was performed by Sequitherm cycle sequencing, according to the manufacturer’s recommendations (Epicentre Technologies, Madison, WI, USA) (Table II).

**Results**
Six colitis associated neoplasia specimens were analysed for DPC4 alterations by PCR amplification and cycle sequencing. A high grade dysplasia from patient CC-4 contained a nonsense mutation of DPC4 in exon 11 (codon 516), which changed a glutamine codon (CAG) to a stop codon (TAG). The mutation was confirmed by sequencing the product of an independently amplified PCR product and by sequencing the PCR product in the opposite direction using another primer. The site of mutation was sequenced from non-neoplastic mucosa from the same patient to establish the somatic nature of the mutation. The Figure gives an example of the sequencing results. Specimen CC-4 was one of three lesions in this study known to have allelic loss of 18q, indicating that the DPC4 gene was biallelically inactivated in this specimen. No other alterations of DPC4 were identified among the six patients. The mutational status of DPC4 was combined with previous data to provide updated molecular genetic profiles for these lesions (Table III).

**Discussion**
We recently identified the candidate tumour suppressor gene DPC4. It was inactivated in nearly half of pancreatic carcinomas. The site

**TABLE III  
DPC4 status and molecular genetic profiles of colitis associated neoplasms**

<table>
<thead>
<tr>
<th>Sample</th>
<th>K-ras*</th>
<th>APC*</th>
<th>Sq Loss</th>
<th>p53</th>
<th>17p Loss</th>
<th>DPC4*</th>
<th>18q Loss</th>
<th>FAL†</th>
<th>RER</th>
</tr>
</thead>
<tbody>
<tr>
<td>CC-1</td>
<td></td>
<td></td>
<td>LOH</td>
<td></td>
<td></td>
<td>LOH</td>
<td></td>
<td>0.43</td>
<td></td>
</tr>
<tr>
<td>CC-2a</td>
<td>12 G → D</td>
<td></td>
<td>1450 R → stop</td>
<td>1951 → T</td>
<td>LOH</td>
<td>0.22</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC-3</td>
<td>12 G → D</td>
<td></td>
<td>1450 R → stop</td>
<td>1951 → T</td>
<td>LOH</td>
<td>0.22</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC-4</td>
<td>1556 fs ins</td>
<td></td>
<td>278 fs del</td>
<td>179 H → Y</td>
<td>LOH</td>
<td>0.22</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC-5a</td>
<td>1354 fs del</td>
<td></td>
<td>262 splice</td>
<td>179 H → Y</td>
<td>LOH</td>
<td>0.22</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC-6a</td>
<td>12 G → D</td>
<td></td>
<td>282 R → W</td>
<td>179 H → Y</td>
<td>LOH</td>
<td>0.22</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC-6b</td>
<td>12 G → D</td>
<td></td>
<td>282 R → W</td>
<td>179 H → Y</td>
<td>LOH</td>
<td>0.22</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

LOH=LOH found; +multiple allelic shifts indicative of RER phenotype; −no LOH, mutations, or allelic shifts detected; ND=not determined. *K-ras, p53, and DPC4 mutations are given by codon and the predicted translation product using the single letter amino acid code. fs del=frameshift deletion mutation; fs ins=frameshift insertion; splice=splice acceptor site mutation. For APC, mutations were identified by a screening assay for mutations producing truncated products, and the failure to identify a mutation due to its absence depends on the possibility of other types of mutations. For DPC4, the presence of homonymous deletions is not excluded. CC-4 had two mutations in APC. CC-6a had a p53 missense mutation on each allele. †FAL=fractional allelic loss. Mutations of DPC4 status from the current study is shown in a genetic context with data from previous publications.1
of DPC4, at 18q21.1 near the DCC gene, is known to be commonly involved in loss of heterozygosity events in colitis associated neoplasms. The deletions of chromosome 18, however, often involve very large regions, and it has been difficult to identify the gene(s) which may serve as the genetic target of these events. Here, we report a DPC4 point mutation in one of three advanced colitis associated neoplasms which harboured allelic loss of 18q. This is the first gene target on 18q to be pinpointed by the identification of a point mutation in colitis associated dysplasia. Interestingly, the mutation was found in the non-invasive dysplastic plaque, rather than the carcinomas. Follow up efforts would benefit from a larger series, which should include an assessment of prognostic importance for lesions having DPC4 inactivation. In addition to inactivation by point mutations, nearly two thirds of the DPC4 gene inactivation in pancreatic cancer occur by homozygous deletion—that is, loss of both copies of the gene. Analysis for this type of genetic event is, however, technically difficult in primary tumours. Primary tumour tissue contains non-neoplastic stromal and inflammatory cells whose normal copies of the DPC4 gene would be amplified in the PCR, thus impairing a direct demonstration of homozygous gene loss. Six of 41 pancreatic tumours contained mutations of the DPC4 gene sequence, not significantly different from the results of the current study. By extension, colitis associated neoplasms might also harbour homozygous deletions of DPC4, which could not be assayed with the methods used here. The intragenic mutation identified in one of the specimens in this series, however, would now justify further dedicated studies of homozygous deletions of DPC4 in colitis associated dysplasias and cancers. For this, specialised techniques will be required, such as microdissection to isolate neoplastic cells, or the detection of “apparent retention of heterozygosity” through the use of polymorphic markers at sites of homozygous deletion in primary tumour tissues. The mutation reported here was a non-sense mutation in exon 11 of the DPC4 gene. Interestingly, five of six DPC4 mutations identified in pancreatic carcinoma also abolished exon 11 of DPC4 through the premature termination of translation. This suggests the applicability of an in vitro synthesised (IVS) protein assay in screening for DPC4 mutations. An advantage of the IVS assay is that it is adequately sensitive for analysis of native biopsy specimens. We have applied this assay successfully for the APC gene in colitis associated neoplasia. K-ras mutations are also currently detectable by various sensitive assay methods, amounting to three genes the alterations of which could be detected in routine biopsy samples during surveillance for colitis associated neoplasia. We have now generated a genetic profile of colitis associated neoplasms including the mutation status of four genes (K-ras, p53, APC, and DPC4). Aside from the potential in diagnostics, the understanding of the interaction of the multiple genetic aberrations in colitis associated neoplasms might also prove to be valuable in the understanding of the clinical progression of these neoplasms.

We thank the residents of the Department of Pathology for tissue collection, the surgeons and gastroenterologists of the Johns Hopkins Hospital for their help in identification of patients and clinical information, and Dr Stanley R Hamilton and Dr John H Yardley for confirmation of dysplasia and adenocarcinoma by tissue procurement. This work was supported by the NIH SPORE in Gastrointestinal Cancer, CA69294. SEK is a McDonnell Foundation Scholar.

DPC4 gene mutation in colitis associated neoplasia.

A T Hoque, S A Hahn, M Schutte and S E Kern

Gut 1997 40: 120-122
do: 10.1136/gut.40.1.120

Updated information and services can be found at:
http://gut.bmj.com/content/40/1/120

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections
Pancreas and biliary tract (1949)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/